University of Pennsylvania

Researchers at the University of Gothenburg found that semaglutide, a diabetes and weight loss medication, reduced cocaine self-administration by 26% in rats compared to control animals.

A first-of-its-kind clinical trial demonstrated that repurposed cancer drugs can effectively target dormant breast cancer cells, clearing them in 80% of participants and potentially preventing cancer recurrence.

The Wistar Institute received a five-year, $17 million NIH grant to launch the iCure Consortium, developing individualized cure regimens for HIV through personalized medicine approaches.

The FDA has approved expansion of Aquedeon Medical's IDE clinical trial for the Duett Vascular Graft System, increasing enrollment from the initial study to up to 90 patients across additional U.S. clinical sites.

Pre-treatment genetic testing for DPYD and UGT1A1 variants reduced severe chemotherapy side effects from 65% to 38% in gastrointestinal cancer patients with genetic variants.

Dispatch Bio, a new biotech company formed through collaboration between Arch Venture Partners and the Parker Institute for Cancer Immunotherapy, has raised $216 million to develop a universal solid tumor treatment approach.

Soligenix successfully transferred manufacturing of synthetic hypericin from Europe to the U.S. through partnership with Sterling Pharma Solutions, establishing scalable cGMP production for clinical trials.

UCLA Health researchers analyzed 3,500 hospitalized COVID-19 patients and found unvaccinated individuals were 16% more likely to require continuous renal replacement therapy during hospitalization.

Northwest Biotherapeutics' Chief Technical Officer Dr. Marnix Bosch will present on "supercharged" dendritic cells with enhanced anti-tumor effects at the Frontiers in Cancer Immunotherapy Conference on June 16.

Researchers from the University of Pennsylvania, including the School of Veterinary Medicine, Perelman School of Medicine, and Children's Hospital of Philadelphia, have developed modified mRNA vaccines incorporating cytokine IL-12 that significantly enhance CD8+ T cell responses.